Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

NCT00972933 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: ipilimumab

Sponsor

Diwakar Davar

Collaborators

[object Object]